Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy.
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Eur J Endocrinol. 2020 Nov;183(5):521-528. doi: 10.1530/EJE-20-0682.
The ultrasonographic scores EU TI-RADS and ACR TI-RADS were introduced to give the clinicians indications for fine needle aspiration cytology (FNAC). The predictive role of these scores was never evaluated and compared in a surgical series of patients. The aim of this study was to evaluate the ex post diagnostic accuracy of EU TI-RADS and ACR TI-RADS in a real-life series of thyroidectomized patients and to evaluate the 'missing' thyroid cancer following the operational indications of these scores.
Retrospective monocentric cohort study.
In total, 255 patients (harboring 304 nodules) undergoing thyroidectomy for benign and malignant thyroid conditions were enrolled. The prevalence of thyroid malignancy for each class of ACR TI-RADS and EU TI-RADS, their diagnostic accuracy, the number of 'unnecessary' FNAC and the number of 'missed' cancers were evaluated.
ACR TI-RADS and EU TI-RADS score had similar and satisfactory accuracy values for predicting thyroid malignancy (AUC: 0.835 for ACR TI-RADS vs 0.827 for EU TI-RADS). The ACR TI-RADS and EU TI-RADS categories (suspicious vs non-suspicious), age, sex and presence of a single nodule significantly and independently predicted the presence of malignancy in a logistic regression model. An ex post analysis according to the indications for FNAC for each score indicated that 31 and 16 cases of cancer would have been missed by ACR TI-RADS and EU TI-RADS scores, respectively.
ACR TI-RADS and EU TI-RADS display a good performance in predicting thyroid cancer when histology is taken as reference standard, but additional clinical judgement is required to decide the indication for FNAC.
引入超声评分 EU TI-RADS 和 ACR TI-RADS,为临床医生提供细针抽吸细胞学检查(FNAC)的指征。这些评分的预测作用从未在一系列外科患者中进行过评估和比较。本研究旨在评估 EU TI-RADS 和 ACR TI-RADS 在一系列真实甲状腺切除患者中的事后诊断准确性,并评估这些评分的手术指征下“遗漏”的甲状腺癌。
回顾性单中心队列研究。
共纳入 255 例(304 个结节)因良性和恶性甲状腺疾病行甲状腺切除术的患者。评估每个 ACR TI-RADS 和 EU TI-RADS 类别中的甲状腺恶性肿瘤的患病率、其诊断准确性、“不必要”FNAC 的数量以及“遗漏”癌症的数量。
ACR TI-RADS 和 EU TI-RADS 评分在预测甲状腺恶性肿瘤方面具有相似且令人满意的准确性值(ACR TI-RADS 的 AUC:0.835 对 EU TI-RADS 的 0.827)。ACR TI-RADS 和 EU TI-RADS 类别(可疑对非可疑)、年龄、性别和单个结节的存在在逻辑回归模型中显著且独立地预测了恶性肿瘤的存在。根据每个评分的 FNAC 指征进行的事后分析表明,ACR TI-RADS 和 EU TI-RADS 评分分别会遗漏 31 例和 16 例癌症病例。
当以组织学为参考标准时,ACR TI-RADS 和 EU TI-RADS 在预测甲状腺癌方面表现出良好的性能,但需要额外的临床判断来决定 FNAC 的指征。